Biological Chemistry and Drug Discovery
In an article published today in the prestigious journal Nature Chemical Biology, scientists at the University of Dundee and Boehringer Ingelheim have made an important first stride toward drugging undruggable cancer targets using an innovative approach to drug discovery.
Researchers in the laboratory of Professor Alessio Ciulli have revealed atomic-resolution images of how an E3 ubiquitin ligase enzyme involved in immune and cell signalling latches on to its protein partners. This is important because these binding events are required for the protein to function properly inside the cell.
Professor Alessio Ciulli’s laboratory is seeking a postdoctoral researcher to undertake research in collaboration with the major pharmaceutical company Eisai Co. Ltd. The project will apply novel cell biology and biochemical approaches to targeted protein degradation and investigate application of novel degrader molecules to treat cancers and elucidate their mechanism of action.
Around 60 aspiring entrepreneurs from across Scotland’s Universities are now through to the next stage of Converge, Scotland’s leading academic enterprise programme. Five projects from the University of Dundee, two from the School, have been selected for this stage of the Challenge. The projects from researchers based in Life Sciences are Ten Biotech and In4Derm.
Grade 7 (£32,236-£39,609) or Grade 6 (£26,243-£32,236) depending on experience and skill set.